HOW to obtain a copy of these reports
NEXT REPORT TO BE PUBLISHED IS: CIRCULATORY AND MENTAL HEALTH - TO COMPLETE THE REPORTS IN THIS SERIES FOR 2015
SEE BELOW FOR REPORTS PUBLISHED THUS FAR IN 2016:
THE CORPORATE REPUTATION OF PHARMA 2015 (NEUROLOGICAL EDITION)
- THE PATIENT PERSPECTIVE
The 29 companies analysed:
AbbVie I Actavis I Allergan I Amgen I AstraZeneca I Bayer I Biogen Idec I Boehringer Ingelheim I Bristol-Myers Squibb I Eisai I Grünenthal I GSK I Ipsen I Janssen I Lundbeck I Merck & Co I Merck KGaA I Mylan I Novartis I Pfizer I Roche I Sandoz I Sanofi I Servier I Shire I Takeda I Teva I UCB
London, published April 25th, 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 257 neurological patient groups worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 29 pharma companies for six key indicators that influence corporate reputation. Results are compared with those of the previous year.

The report also offers, as a case study survey responses from one Israeli company, Teva. Teva explains what they are doing on the subject of global patient centricity, and comment about their relationships with patient groups. 
THE CORPORATE REPUTATION OF PHARMA 2015 (SKIN EDITION)
- THE PATIENT PERSPECTIVE
The 20 companies analysed:
AbbVie I Actavis I Amgen I AstraZeneca I Bayer I Boehringer Ingelheim I Bristol-Myers Squibb I Celgene I GSK I Janssen I Leo Pharma I Lilly I Merck & Co I Novartis I Pfizer I Roche I Sandoz I Sanofi I Teva I UCB

To obtain more details about this report click on links below:
London, published May 9th, 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 110 patient groups with an interest in skin worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 20 pharma companies for six key indicators that influence corporate reputation. Results are compared with those of the previous year.

The report also offers, as a case study survey responses from one Danish company, Leo Pharma. Leo Pharma explains what they are doing on the subject of global patient centricity, and comment about their relationships with patient groups.
cover_and_contents_skin_patientview.pdf
File Size: 971 kb
File Type: pdf
Download File
For a statement about this report go to:
http://createsend.com/t/j-C06877A4D2D89364
THE CORPORATE REPUTATION OF PHARMA 2015 (RARE DISEASE EDITION)
- THE PATIENT PERSPECTIVE
Statement about this report:
http://createsend.com/t/j-4B5B2AF8179759B3
London, published May 17th, 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 199 patient groups with an interest in rare diseases worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 28 pharma companies for six key indicators that influence corporate reputation. Results are compared with those of the previous year.
The 28 companies analysed:
AbbVie I Actavis I Allergan I Amgen I AstraZeneca I Baxalta I Bayer I Biogen Idec I Boehringer Ingelheim I Bristol-Myers Squibb I Celgene I Gilead I GSK I Janssen I Lilly I Lundbeck I Merck & Co I Merck KGaA I Novartis I Novo Nordisk I Pfizer I Roche I Sandoz I Sanofi I Shire I Takeda I Teva I UCB

To obtain more details about this report click on links below:
rare_cover_and_contents_patientview.pdf
File Size: 1393 kb
File Type: pdf
Download File
THE CORPORATE REPUTATION OF PHARMA 2015 (DIABETES EDITION)
- THE PATIENT PERSPECTIVE
London, published August 8th, 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 139 patient groups with an interest in diabetes worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 21 pharma companies for six key indicators that influence corporate reputation. Results are compared with those of the previous year.
The 21 companies analysed:
AbbVie I Actavis I Amgen I AstraZeneca I Bayer I Boehringer Ingelheim I Bristol-Myers Squibb I Eli Lilly (Lilly) I GSK I Janssen I Menarini I Merck & Co I Novartis I Novo Nordisk I Pfizer I Roche I Sandoz I Sanofi I Servier I Takeda I Teva
 
To obtain more details about this report click on links below:
diabetes_cover___contents_patientview.pdf
File Size: 1079 kb
File Type: pdf
Download File
Highlights of this report can be read here:
http://createsend.com/t/j-6E98975C52450A26
THE CORPORATE REPUTATION OF PHARMA 2015 (HEPATITIS EDITION)
- THE PATIENT PERSPECTIVE
To read more details about this report click on the link below:
http://createsend.com/t/j-3026B6FBD2FC6604
London, published August 24th, 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 111 patient groups with an interest in hepatitis worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 14 pharma companies for six key indicators that influence corporate reputation. Results are compared with those attained across all therapy areas in 2015.
The 14 companies analysed:
AbbVie I Bayer I Boehringer Ingelheim I Bristol-Myers Squibb I Gilead Sciences I GSK I Janssen I Merck & Co I Novartis I Pfizer I Roche I Sandoz I Sanofi I ViiV healthcare

To obtain more details about this report click on links below:
hepatitis_cover_and_contents_patientview.pdf
File Size: 1122 kb
File Type: pdf
Download File
THE CORPORATE REPUTATION OF PHARMA 2015 (HIV/AIDS EDITION)
- THE PATIENT PERSPECTIVE
London, published September 5th 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 107 patient groups with an interest in HIV/AIDS worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 12 pharma companies for six key indicators that influence corporate reputation. Results are compared with those attained across all therapy areas in 2015.
The 12 companies analysed:
AbbVie I Boehringer Ingelheim I Bristol-Myers Squibb I Gilead Sciences I GSK I Janssen I Merck & Co I Novartis I Pfizer I Roche I  Sanofi I ViiV healthcare

To obtain more details about this report click on links below:
cover_and_contents_hiv-aids.pdf
File Size: 1246 kb
File Type: pdf
Download File
THE CORPORATE REPUTATION OF PHARMA 2015 (CANCER EDITION)
- THE PATIENT PERSPECTIVE
London, published 18th October 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 280 patient groups with an interest in cancer worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 31 pharma companies for six key indicators that influence corporate reputation. Results are compared with those attained across all therapy areas in 2015.
The 31 companies analysed:
AbbVie I Amgen I Astellas I AstraZeneca I Baxalta I Bayer I Biogen Idec I Boehringer Ingelheim I Bristol-Myers Squibb I Celgene I Eisai I Eli Lilly (Lilly) I Ferring I Gilead Sciences I Grünenthal I GSK I Ipsen I Janssen I Leo Pharma I Lundbeck I Merck & Co I Merck KGaA I Novartis I Pfizer I Roche I Sandoz I Sanofi I Servier I Shire I Takeda I Teva

To obtain more details about this report click on links below:
cover_and_contents_cancer_corp_rep_2015_patientview.pdf
File Size: 928 kb
File Type: pdf
Download File
LINK TO THE STATEMENT OF REPORT
THE CORPORATE REPUTATION OF PHARMA 2015 (RESPIRATORY EDITION)
- THE PATIENT PERSPECTIVE
London, published 27th October 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 118 patient groups with an interest in respiratory conditions worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 15 pharma companies for six key indicators that influence corporate reputation. Results are compared with those attained across all therapy areas in 2015.
The 15 companies analysed:
AbbVie I Amgen I AstraZeneca I Bayer I Boehringer Ingelheim I Eli Lilly (Lilly) I GSK I  Janssen I Merck & Co I Novartis I Pfizer I Roche I Sandoz I Sanofi I Teva

To obtain more details about this report click on links below:
cover___contents_respiratory_corp_rep_patientview.pdf
File Size: 751 kb
File Type: pdf
Download File
LINK TO STATEMENT OF THE REPORT
THE CORPORATE REPUTATION OF PHARMA 2015 (CIRCULATORY EDITION)
- THE PATIENT PERSPECTIVE
London, to be published 7th November 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 90 patient groups with an interest in heart and circulatory conditions worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 15 pharma companies for six key indicators that influence corporate reputation. Results are compared with those attained across all therapy areas in 2015.
The 15 companies analysed:
AbbVie I Amgen I AstraZeneca I Bayer I Boehringer Ingelheim I Bristol Myers-Squibb I Eli Lilly (Lilly) I GSK I  Janssen I Merck & Co I Novartis I Pfizer I Roche I Sandoz I Sanofi

To obtain more details about this report click on links below:
circulatory_corp_rep_cover_and_contents.pdf
File Size: 843 kb
File Type: pdf
Download File
THE CORPORATE REPUTATION OF PHARMA 2015 (MENTAL HEALTH EDITION)
- THE PATIENT PERSPECTIVE
mental_health_cover_and_contents_2015_patientview.pdf
File Size: 849 kb
File Type: pdf
Download File
London, to be published 14th November 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 209 patient groups with an interest in mental health conditions worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 20 pharma companies for six key indicators that influence corporate reputation. Results are compared with those attained across all therapy areas in 2015.
The 20 companies analysed:
AbbVie I Actavis I AstraZeneca I Boehringer Ingelheim I Bristol-Myers Squibb I Eli Lilly (Lilly) I GSK I Janssen I Lundbeck I Merck & Co I Novartis I Otsuka I Pfizer I Roche I Sandoz I Sanofi I Servier I Shire I Takeda I Teva

To obtain more details about this report click on links  on the left